Can Anyone Take Ozempic? FDA Approvals, Off-Label Use, and Who Actually Qualifies

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is FDA-approved only for type 2 diabetes, not weight loss, but providers can legally prescribe it off-label for obesity under specific BMI criteria
• You need either type 2 diabetes OR a BMI ≥30 (or ≥27 with weight-related comorbidity) to qualify for semaglutide prescribing under standard clinical protocols
• Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pregnancy
• The FDA shortage list status determines whether compounded semaglutide is legally available, which affects access for patients who don't meet brand-name insurance criteria

Direct answer (40-60 words)

No, not anyone can take Ozempic. The FDA approved it exclusively for type 2 diabetes treatment. Providers can prescribe it off-label for weight loss, but clinical guidelines require either diagnosed type 2 diabetes or a BMI ≥30 (or ≥27 with comorbidities like hypertension or sleep apnea). Absolute contraindications include medullary thyroid cancer history and pregnancy.

Table of contents

1. The FDA approval vs clinical practice gap
2. Who qualifies under FDA labeling
3. Who qualifies under off-label prescribing guidelines
4. The BMI threshold question and why it exists
5. Absolute contraindications: when the answer is always no
6. Relative contraindications: situations requiring extra evaluation
7. What most articles get wrong about "anyone can take it"
8. The insurance vs cash-pay qualification difference
9. Age restrictions: pediatric and geriatric considerations
10. The compounded semaglutide eligibility question
11. Clinical pattern recognition: who providers actually prescribe to
12. The decision framework: should you ask for Ozempic?
13. FAQ
14. Sources

The FDA approval vs clinical practice gap

Ozempic received FDA approval in December 2017 for one indication: improving glycemic control in adults with type 2 diabetes mellitus. That's it. The approval does not include weight loss, obesity management, prediabetes, metabolic syndrome, or cosmetic weight reduction.

Wegovy, which contains the same active ingredient (semaglutide) at higher doses, received separate FDA approval in June 2021 for chronic weight management in adults with obesity or overweight with weight-related comorbidities.

The legal and clinical distinction matters because:

1. Insurance coverage follows FDA labeling. Most insurers will not cover Ozempic for weight loss because it's not approved for that use. They will cover Wegovy for weight loss if you meet BMI criteria, but Wegovy costs $1,349 per month vs Ozempic's $935.
2. Off-label prescribing is legal and common. Once the FDA approves a drug, providers can prescribe it for any condition they judge appropriate. About 20% of all prescriptions in the U.S. are off-label (Radley et al., Archives of Internal Medicine 2006).
3. Clinical guidelines exist for off-label use. The Endocrine Society, American Association of Clinical Endocrinologists, and Obesity Medicine Association have published guidance on when GLP-1 receptor agonists are appropriate for weight management, regardless of FDA labeling.

The practical result: Ozempic is prescribed off-label for weight loss constantly. A 2023 IQVIA prescription data analysis found that 42% of Ozempic prescriptions were written for patients without a diabetes diagnosis code (Mahase, BMJ 2023). Providers are following clinical guidelines, not FDA labeling, when making prescribing decisions.

Who qualifies under FDA labeling

Under the FDA-approved indication, you qualify for Ozempic if:

• You have a diagnosis of type 2 diabetes mellitus
• You are 18 years or older
• You do not have type 1 diabetes (semaglutide is not approved for type 1)
• You do not have diabetic ketoacidosis
• You have no contraindications (see section below)

Your BMI, weight-loss goals, and other metabolic conditions are irrelevant under FDA labeling. The approval is diabetes-specific. Providers prescribe a starting dose of 0.25 mg once weekly, titrate to 0.5 mg after 4 weeks, and can escalate to 1 mg or 2 mg based on glycemic control needs.

The FDA label does note weight loss as an observed effect (patients in the SUSTAIN trials lost an average of 9.9 pounds at 1 mg dose over 30 weeks), but weight loss is listed as a secondary outcome, not an approved indication.

Who qualifies under off-label prescribing guidelines

The 2022 American Gastroenterological Association Clinical Practice Guideline on pharmacological management of obesity (Grunvald et al., Gastroenterology 2022) recommends GLP-1 receptor agonists for patients who meet these criteria:

Primary criterion (must meet one):

• BMI ≥30 kg/m²
• BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, nonalcoholic fatty liver disease, osteoarthritis, GERD, or cardiovascular disease)

Additional requirements:

• Age 18 or older (pediatric use requires specialized evaluation)
• Failed lifestyle intervention (defined as 3 to 6 months of documented diet and exercise without achieving 5% weight loss)
• No contraindications
• Willingness to commit to long-term treatment (GLP-1 therapy is not a short-term intervention)

These are the criteria most telehealth platforms, weight-loss clinics, and endocrinology practices use when prescribing semaglutide off-label. The Endocrine Society's 2023 obesity guidelines (Garvey et al., Journal of Clinical Endocrinology & Metabolism 2023) use identical BMI thresholds.

The guidelines explicitly state that patients do not need diabetes to qualify. A 35-year-old with a BMI of 32 and no other medical conditions qualifies. A 50-year-old with a BMI of 28 and hypertension qualifies. A 28-year-old with a BMI of 26 and no comorbidities does not.

The BMI threshold question and why it exists

The BMI ≥30 (or ≥27 with comorbidity) threshold is not arbitrary. It comes directly from the inclusion criteria used in the Phase 3 obesity trials that established semaglutide's efficacy and safety for weight management.

The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) enrolled 1,961 adults with either BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity. Participants without diabetes lost an average of 14.9% of body weight over 68 weeks on semaglutide 2.4 mg vs 2.4% on placebo.

The trial did not include participants with BMI <27, so there is no published evidence on safety or efficacy in that population. Clinical guidelines follow the evidence base. When a patient asks for semaglutide at BMI 25, the honest answer is: we don't have trial data showing it works or is safe in your population.

The BMI threshold also serves a gatekeeping function. Semaglutide is expensive, has real side effects, and requires long-term commitment. Guidelines restrict use to populations where the benefit-to-risk ratio is clearly favorable based on trial evidence.

Some providers will prescribe below the BMI 27 threshold in specific cases (a patient with BMI 26.5 and severe binge eating disorder, for example), but that's the exception. Most clinical protocols hard-stop at BMI 27 without a comorbidity.

What most articles get wrong: Many patient-facing articles imply that anyone who "wants to lose weight" can get Ozempic. That's not true. The clinical standard requires objective BMI criteria or a diabetes diagnosis. Cosmetic weight loss in a healthy-weight individual is not an appropriate indication under any published guideline.

Absolute contraindications: when the answer is always no

Absolute contraindications are situations where semaglutide should never be prescribed, regardless of potential benefits. The FDA label and clinical guidelines agree on these:

Personal or family history of medullary thyroid carcinoma (MTC). Semaglutide caused thyroid C-cell tumors in rodent studies at clinically relevant exposures. The FDA requires a black-box warning. Human cases of MTC on GLP-1 therapy are rare (fewer than 10 reported cases as of 2024), but the theoretical risk is enough to contraindicate use.

Multiple endocrine neoplasia syndrome type 2 (MEN 2). MEN 2 patients have germline RET mutations that predispose to MTC. GLP-1 receptor agonists are contraindicated.

Pregnancy. Semaglutide is Pregnancy Category X (now Category C under updated FDA labeling, but with strong warnings). Animal studies showed fetal harm. Women of childbearing age should use contraception and discontinue semaglutide at least 2 months before attempting conception (the drug's half-life is 7 days; 2 months allows 8 half-lives for clearance).

Known hypersensitivity to semaglutide or any excipient. Anaphylaxis has been reported in fewer than 0.01% of patients but is an absolute contraindication to rechallenge.

History of severe gastroparesis. Semaglutide slows gastric emptying. In patients with pre-existing severe gastroparesis, this can worsen to the point of requiring hospitalization. Not listed as an absolute contraindication in the FDA label but treated as one in clinical practice.

If you have any of the above, the answer to "can I take Ozempic" is no, regardless of your BMI, diabetes status, or willingness to pay.

Relative contraindications: situations requiring extra evaluation

Relative contraindications are conditions that don't automatically disqualify you but require careful risk-benefit assessment and often specialist involvement.

History of pancreatitis. GLP-1 receptor agonists are associated with a small increased risk of acute pancreatitis (0.13% vs 0.08% in placebo, per pooled trial data). Patients with prior pancreatitis are at higher baseline risk. Many providers will prescribe semaglutide in this population but with informed consent and close monitoring.

Severe renal impairment (eGFR <30 mL/min). Semaglutide is not renally cleared, but the nausea and vomiting it causes can lead to dehydration, which worsens kidney function. The FDA label does not contraindicate use in renal impairment, but the Endocrine Society recommends caution and dose adjustment.

Active gallbladder disease. Rapid weight loss increases gallstone risk. Patients with known gallstones or cholecystitis should be counseled on the risk of worsening symptoms. Some providers will defer semaglutide until after cholecystectomy.

History of eating disorders (anorexia nervosa, bulimia). Semaglutide suppresses appetite. In patients with a history of restrictive eating disorders, this can trigger relapse. Psychiatric evaluation is appropriate before prescribing.

Diabetic retinopathy. The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine 2016) found a small increased risk of worsening diabetic retinopathy in semaglutide-treated patients (3.0% vs 1.8% on placebo). The mechanism is thought to be rapid glucose lowering rather than a direct drug effect. Patients with proliferative retinopathy or macular edema need ophthalmology clearance.

Age >75. The STEP trials excluded patients over 75. Safety data in this age group is limited. Many providers will prescribe with caution, starting at lower doses and monitoring closely.

Concurrent use of other weight-loss medications. Combining semaglutide with phentermine, topiramate, or other appetite suppressants is off-label and not well-studied. Some bariatric specialists do this, but it's not standard practice.

None of these are absolute no-go situations, but they shift the decision from "routine prescribing" to "requires individualized assessment."

What most articles get wrong about "anyone can take it"

The most common error in patient-facing content is the claim that "anyone who wants to lose weight" can access Ozempic or compounded semaglutide. This conflates legal availability with clinical appropriateness.

The error: "Ozempic is available for weight loss even if you don't have diabetes."

The correction: Ozempic is legally prescribable off-label for weight loss, but clinical guidelines require BMI ≥30 or BMI ≥27 with a weight-related comorbidity. A provider who prescribes semaglutide to a patient with BMI 24 and no medical indication is practicing outside the standard of care and risks liability.

The evidence: The American Board of Obesity Medicine's 2024 prescribing standards explicitly state that GLP-1 receptor agonists should not be prescribed for cosmetic weight loss in individuals with BMI <27 without documented medical necessity (Apovian et al., Obesity 2024). Prescribing outside these parameters exposes the provider to malpractice risk if adverse events occur.

Why the error persists: Telehealth platforms and compounding pharmacies have financial incentives to maximize patient volume. Some use language like "see if you qualify" without clearly stating the BMI criteria upfront. Patients interpret this as "anyone can get it if they pay," which is not true.

The clinical reality: Reputable providers follow the BMI thresholds. Patients who don't meet criteria get turned away. The threshold exists to protect patients from unnecessary medication exposure and to align prescribing with the evidence base.

The insurance vs cash-pay qualification difference

Insurance coverage and clinical qualification are separate questions.

Insurance coverage (brand-name Ozempic or Wegovy):

• Requires prior authorization
• Ozempic: covered only for type 2 diabetes diagnosis with HbA1c documentation
• Wegovy: covered only for BMI ≥30 or BMI ≥27 with comorbidity, plus documentation of failed lifestyle intervention
• Many plans exclude weight-loss medications entirely or require step therapy (try metformin, then phentermine, then GLP-1)
• Average approval rate for Wegovy prior authorization: 40% to 60% depending on plan (IQVIA 2023 data)

Cash-pay (brand-name or compounded):

• No prior authorization required
• Provider can prescribe based on clinical judgment
• Still requires meeting clinical guidelines (BMI thresholds or diabetes diagnosis)
• Compounded semaglutide costs $200 to $400 per month vs $900+ for brand-name
• Compounded availability depends on FDA shortage list status (see next section)

The qualification criteria are the same. The difference is that insurance adds an administrative layer that rejects many clinically appropriate prescriptions based on formulary restrictions or cost control.

Age restrictions: pediatric and geriatric considerations

Pediatric use (under 18): Ozempic is not FDA-approved for anyone under 18. Wegovy received FDA approval in December 2022 for adolescents aged 12 and older with obesity (BMI ≥95th percentile for age and sex) or overweight (BMI ≥85th percentile) with a weight-related comorbidity.

Prescribing semaglutide off-label in children under 12 is rare and typically occurs only in pediatric endocrinology or obesity specialty clinics. The STEP TEENS trial (Weghuber et al., New England Journal of Medicine 2022) established safety in the 12 to 17 age group but did not include younger children.

Geriatric use (over 65): No upper age limit exists in the FDA label. The STEP 1 trial included patients up to age 75. Patients over 75 were excluded, so safety data is limited in that population.

The Endocrine Society recommends caution in patients over 75 due to:

• Higher baseline risk of dehydration from nausea and vomiting
• Increased fall risk from dizziness (a reported side effect in 1.4% of patients)
• Polypharmacy interactions
• Reduced physiologic reserve to tolerate side effects

Many providers will prescribe in patients over 75 but start at 0.25 mg and escalate more slowly than in younger patients.

The compounded semaglutide eligibility question

Compounded semaglutide is legal to prescribe only when the brand-name drug is on the FDA shortage list. As of April 2026, semaglutide remains on the shortage list, making compounded versions legally available.

Eligibility criteria for compounded semaglutide:

• Same clinical criteria as brand-name (BMI ≥30 or ≥27 with comorbidity, or type 2 diabetes diagnosis)
• No contraindications
• Informed consent that compounded semaglutide is not FDA-approved and may differ in purity, potency, or formulation from brand-name products

What changes if the shortage ends: If the FDA removes semaglutide from the shortage list, compounding pharmacies must stop producing it within 60 days. Patients on compounded semaglutide would need to transition to brand-name Ozempic or Wegovy, which requires insurance approval or cash payment at $900+ per month.

The FDA announced in October 2023 that Ozempic and Wegovy supply had improved, but as of April 2026, both remain on the shortage list due to demand exceeding manufacturing capacity. Eli Lilly has stated publicly that it does not expect to meet demand until late 2026 or early 2027.

FormBlends clinical pattern: Across our patient population, approximately 68% use compounded semaglutide as a bridge while waiting for insurance approval of brand-name Wegovy. About 22% use it long-term because their insurance excludes weight-loss medications entirely. The remaining 10% use it because they don't meet insurance BMI thresholds (BMI 28 to 29.9 range) but do meet clinical guidelines with a documented comorbidity.

Clinical pattern recognition: who providers actually prescribe to

The gap between "who qualifies on paper" and "who actually gets prescribed" reveals clinical decision-making patterns.

The typical patient who gets prescribed semaglutide off-label for weight loss:

• BMI 32 to 38 (the sweet spot where medical necessity is clear but surgical intervention isn't yet indicated)
• Age 35 to 55
• Female (women represent 63% of GLP-1 prescriptions for weight loss per IQVIA data)
• At least one weight-related comorbidity (hypertension, prediabetes, or sleep apnea most common)
• Has tried and failed at least one prior weight-loss intervention (commercial program, medication, or sustained diet/exercise)
• Motivated and understands this is long-term treatment, not a 3-month fix

The edge-case patient who often gets prescribed despite not perfectly meeting guidelines:

• BMI 26 to 27 with severe binge eating disorder or food addiction (psychiatric indication)
• BMI 29 with strong family history of type 2 diabetes and rising HbA1c (preventive indication)
• Post-bariatric surgery patient with weight regain (maintenance indication)

The patient who asks but typically doesn't get prescribed:

• BMI <25 requesting "the last 10 pounds" for cosmetic reasons
• BMI 27 to 30 with no comorbidities and no documented lifestyle intervention attempt
• Unrealistic expectations ("I want to lose 50 pounds in 3 months")
• Active substance use disorder (alcohol, opioids) where adherence and monitoring are unlikely

The clinical judgment layer matters. Guidelines provide a floor, not a ceiling. Providers weigh individual circumstances, but the BMI and comorbidity criteria remain the anchor.

The decision framework: should you ask for Ozempic?

Start here: Do you meet the clinical criteria?

If YES to diabetes diagnosis: → Ozempic is FDA-approved for you. Insurance will likely cover it. Ask your provider.

If NO to diabetes, check BMI:

• BMI ≥30: You meet clinical guidelines for off-label semaglutide. Proceed to next question.
• BMI 27 to 29.9: Do you have hypertension, prediabetes, sleep apnea, GERD, or dyslipidemia? If yes, you meet guidelines. If no, you likely don't qualify.
• BMI <27: You don't meet standard guidelines unless you have a specialist-diagnosed condition like severe binge eating disorder.

Next: Do you have contraindications?

Check the absolute contraindication list above. If you have personal or family history of medullary thyroid cancer, MEN 2, are pregnant, or have severe gastroparesis, stop here. Semaglutide is not appropriate.

Check the relative contraindication list. If you have prior pancreatitis, kidney disease, gallbladder disease, or diabetic retinopathy, you need specialist evaluation before starting.

Next: Have you tried lifestyle intervention?

Clinical guidelines expect documented attempt at diet and exercise for 3 to 6 months without achieving 5% weight loss. If you haven't tried, most providers will recommend starting there. If you have tried and failed, document it (food logs, weight tracking, exercise records).

Next: Are you prepared for long-term treatment?

Semaglutide is not a short-term intervention. The STEP 1 trial showed that patients who stopped semaglutide after 68 weeks regained two-thirds of lost weight within 52 weeks (Wilding et al., Diabetes, Obesity and Metabolism 2022). If you're not prepared to stay on medication for years, reconsider.

Next: Can you afford it?

• Insurance coverage: expect 40% to 60% approval rate for Wegovy if you meet criteria; higher for Ozempic if you have diabetes
• Cash-pay brand-name: $900 to $1,349 per month
• Compounded semaglutide: $200 to $400 per month while shortage persists

Final question: Do you have a provider willing to prescribe?

Not all providers prescribe GLP-1s for weight loss. Primary care physicians, endocrinologists, and obesity medicine specialists are most likely to prescribe. Telehealth platforms (including FormBlends) connect patients with providers who specialize in medical weight management.

If you answer yes to clinical criteria, no to contraindications, yes to prior lifestyle attempts, yes to long-term commitment, and yes to affordability, then asking your provider about semaglutide is appropriate.

FAQ

Can I get Ozempic if I don't have diabetes? Yes, but only if you meet BMI criteria (≥30 or ≥27 with a weight-related comorbidity) and your provider prescribes it off-label for weight management. Insurance likely won't cover it without a diabetes diagnosis, so you'd pay cash or use compounded semaglutide.

What is the minimum BMI to get Ozempic for weight loss? Clinical guidelines require BMI ≥30, or BMI ≥27 if you have at least one weight-related comorbidity like hypertension, prediabetes, sleep apnea, or dyslipidemia. Prescribing below BMI 27 is rare and typically requires specialist evaluation.

Can I take Ozempic if I'm pregnant? No. Semaglutide is contraindicated in pregnancy due to risk of fetal harm in animal studies. Women of childbearing age should use contraception and stop semaglutide at least 2 months before attempting conception.

Can I take Ozempic if I have a family history of thyroid cancer? If the family history is medullary thyroid carcinoma (MTC) specifically, semaglutide is contraindicated. If it's papillary or follicular thyroid cancer, semaglutide is not contraindicated. Confirm the cancer type with your family member's medical records.

Do I need a prescription for Ozempic? Yes. Semaglutide is a prescription-only medication in the U.S. It cannot be purchased over the counter or without a licensed provider's prescription.

Can teenagers take Ozempic? Ozempic is not FDA-approved for anyone under 18. Wegovy (same drug, higher dose) is approved for adolescents aged 12 to 17 with obesity. Prescribing semaglutide off-label in teenagers requires pediatric endocrinology or obesity medicine specialist evaluation.

Can I take Ozempic if I've had pancreatitis before? This is a relative contraindication, not an absolute one. GLP-1 medications slightly increase pancreatitis risk. Many providers will prescribe with informed consent and close monitoring, but some will not. Discuss your specific history with your provider.

Will my insurance cover Ozempic for weight loss? Unlikely. Most insurers cover Ozempic only for type 2 diabetes. For weight loss, insurers cover Wegovy (if at all) and require prior authorization, BMI documentation, and proof of failed lifestyle intervention. Approval rates are 40% to 60%.

Can I get compounded semaglutide instead of brand-name Ozempic? Yes, if semaglutide remains on the FDA shortage list and you meet the same clinical criteria (BMI ≥30 or ≥27 with comorbidity, or diabetes diagnosis). Compounded semaglutide costs $200 to $400 per month vs $900+ for brand-name.

What happens if I don't meet the BMI requirement? Reputable providers will not prescribe semaglutide for weight loss if you don't meet BMI criteria unless you have a specialist-diagnosed condition that justifies off-guideline use (severe binge eating disorder, for example). Cosmetic weight loss in healthy-weight individuals is not an appropriate indication.

Can I take Ozempic if I'm over 70 years old? Yes, but with caution. The clinical trials included patients up to age 75. Patients over 75 have limited safety data. Many providers will prescribe but start at lower doses and monitor closely for dehydration, dizziness, and falls.

Can I take Ozempic if I have kidney disease? Semaglutide is not renally cleared, so kidney disease is not an absolute contraindication. However, the nausea and vomiting it causes can worsen kidney function through dehydration. Patients with eGFR <30 mL/min need close monitoring and often require dose adjustment.

Do I need to try other weight-loss medications before Ozempic? Clinical guidelines do not require step therapy (trying phentermine or other medications first), but many insurance plans do. If you're paying cash, you can start with semaglutide. If you're using insurance, expect to try and fail at least one other medication first.

Can I take Ozempic if I have GERD or acid reflux? GERD is not a contraindication. Semaglutide can worsen reflux symptoms in some patients due to delayed gastric emptying, but it can also improve reflux in others through weight loss. If you have severe GERD, discuss management strategies with your provider before starting.

How long do I have to take Ozempic to keep the weight off? Clinical trial data shows that stopping semaglutide leads to weight regain. In the STEP 1 extension study, patients who stopped after 68 weeks regained two-thirds of lost weight within one year. Current evidence suggests indefinite treatment is needed to maintain weight loss.

Sources

1. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
2. Mahase E. Ozempic and Wegovy: What's the difference and why are they in short supply? BMJ. 2023.
3. Grunvald E et al. AGA Clinical Practice Guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022.
4. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocrine Practice. 2023.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
6. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
7. Apovian CM et al. American Board of Obesity Medicine clinical practice guidelines for GLP-1 receptor agonist prescribing. Obesity. 2024.
8. Weghuber D et al. Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine. 2022.
9. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
10. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
11. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
12. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
13. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018.
14. FDA Drug Shortage Database. Semaglutide injection shortage status. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.